Skip to main
  1. Stocks
  2. Wave Life Sciences Inc
  3. Forecast
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Wave Life Sciences is supported by a differentiated PRISM platform that spans RNA editing, antisense silencing, and RNA interference, giving it multiple shots on goal across rare and prevalent diseases rather than relying on a single asset. The clearest fundamental driver is WVE-006, where FDA alignment on a single two-year registrational trial with a one-year biomarker interim and use of the company’s LC-MS assay reduces regulatory friction, while clinical biomarker data already show meaningful AAT restoration and Z-AAT reduction. Wave also has a strong balance of platform validation and financial runway, with GSK-selecting a SpiNA candidate triggering a $12M milestone and about $431.0M in cash and investments supporting operations into 3Q28, alongside WVE-007, WVE-008, and other programs that expand long-term upside.

Bears say

Wave Life Sciences is facing substantial clinical and regulatory uncertainty, as efficacy and safety updates from its programs may fail to meet the approval bar and regulators could impose additional requirements or disagree with management’s interpretation of the FDA genome-editing long-term follow-up guidance. Competitive timing also looks unfavorable, with BEAM-302 potentially reaching U.S. AA ahead of WVE-006, while the lack of disclosed trial size, interim cut, or endpoints leaves the development timeline vulnerable to delay. Even if clinical data are positive, commercialization remains risky because competing RNA-silencing platforms could pressure market share and the company may need additional financing, raising dilution risk before profitability.

WVE has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

WVE Analyst Forecast & Price Prediction

Get the latest WVE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WVE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences Inc (WVE) Forecast

Analysts have given WVE a Strong Buy based on their latest research and market trends.

According to 15 analysts, WVE has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences Inc (WVE)


WVE Analyst Forecast & Price Prediction

Get the latest WVE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in WVE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover WVE stock data and trends